GenoSure PRIme® is the first HIV resistance test to provide genotypic resistance information for all Department of Health and Human Services (DHHS)-preferred first-line options, including integrase inhibitors.
GenoSure PRIme is a comprehensive resistance test for four classes of HIV drugs, including protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and integrase inhibitors (INIs). Click here to view a sample report.
Consider GenoSure PRIme for baseline HIV resistance and detection of transmitted resistance at initiation of therapy.1
To Aid in Therapy Decisions for Treatment-experienced Patients
Consider GenoSure PRIme when contemplating changes to your patient’s course of therapy because your patient has suboptimal virologic response or viral load rebound.1
Features of GenoSure PRIme
- Evaluates the HIV-1 polymerase (pol) region, including the complete protease and integrase coding regions and amino acids 1-400 of reverse transcriptase.
- Provides an assessment of drug susceptibility: sensitive, resistance possible, or resistant.
- Appropriate for the evaluation of patient specimens with HIV-1 viral loads of >500 copies/mL.
- Results are returned in approximately 7-10 days.
- Uses Monogram’s proprietary HIV-1 genotype algorithm, which is based on a database of more than 100,000 matched HIV-1 genotype-phenotype results.
Click here to view a sample report. For more information, contact Monogram client services at 800-777-0177.
*If the assay fails on the initial attempt, HIV-1 RNA quantitation will be performed. If the result is <500 copies/mL, the viral load will be reported and the client will be billed.